Wegovy 1 mg solution for injection in pre-filled pen
Sponsors
Region Hovedstaden, Novo Nordisk A/S, Casa Di Cura Accreditata Istituto Chirurgico Ortopedico Traumatologico Marco Pasquali, Santiago Dexeus Font Fundacio Privada
Conditions
Cannabis dependence (Cannabis Use Disorder or CUD)Cardiovascular diseaseDiabetes MellitusInfertilityNon-alcoholic steatohepatitis (NASH)Obesity (BMI≥30kg/m2)Obesity and Heart Failure with reduced Ejection FracitionObesity and overweight
Phase 2
FIT-HF - Effect of weight loss on physical and cardiac performance in patients with heart failure and obesity
RecruitingCTIS2023-503753-35-01
Start: 2024-03-20Target: 100Updated: 2025-08-22
A randomized, double-blind, placebo-controlled trial of semaglutide for reducing cannabis use in adults with cannabis use disorder
Not yet recruitingCTIS2025-524163-21-00
Target: 100Updated: 2026-03-30
Phase 3
The effect of semaglutide in subjects with non-cirrhotic non-alcoholic steatohepatitis
Active, not recruitingCTIS2023-506962-30-00
Start: 2021-03-29Target: 219Updated: 2025-11-11
Is the glucagon-like peptide-1 receptor agonist semaglutide able to alleviate mood in patients with major depressive disorder and overweight or obesity? Sema-Mood.
RecruitingCTIS2024-511734-13-04
Start: 2025-05-15Target: 120Updated: 2025-12-23
Impact of Oral Semaglutide on Platelet Reactivity in Patients with Diabetes Mellitus or Overweight with High Risk or established Cardiovascular Disease: the SEMA-PLAT Study
Not yet recruitingCTIS2025-522486-29-01
Target: 212Updated: 2026-04-23